touchPODCAST

touchpodcast
  • 5.0 (1)
  • SCIENCE
  • UPDATED DAILY
touchPODCAST

Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.

  1. 6 DAYS AGO

    Primary biliary cholangitis: Appraising the changing therapeutic landscape

    touchEXPERT OPINIONS for touchIMMUNOLOGY Listen to a leading expert in hepatology as they explore the current and future management of primary biliary cholangitis.  The expert Dr Mitchell Shiffman - Bon Secours Liver Institute, Richmond, VA, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical educational grant from Gilead Sciences Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchimmunologyime.org/Primary-biliary-cholangitis-therapeutic-landscape

    36 min

  2. 6 DAYS AGO

    Primary biliary cholangitis: Appraising the changing therapeutic landscape

    touchEXPERT OPINIONS for touchENDOCRINOLOGY Listen to a leading expert in hepatology as they explore the current and future management of primary biliary cholangitis.  The expert Dr Mitchell Shiffman - Bon Secours Liver Institute, Richmond, VA, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical educational grant from Gilead Sciences Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  https://touchendocrinologyime.org/primary-biliary-cholangitis-therapeutic-landscape

    36 min

  3. 14 NOV

    touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4

    touchMDT for touchONCOLOGYListen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK.This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.For further information visit our website:  www.touchONCOLOGY.com

    14 min

  4. 14 NOV

    touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3

    touchMDT for touchONCOLOGYListen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK.This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.For further information visit our website:  www.touchONCOLOGY.com

    16 min

  5. 14 NOV

    touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4

    touchMDT for touchRESPIRATORYListen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK.This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.For further information visit our website:  www.touchRESPIRATORY.com

    14 min

  6. 14 NOV

    touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3

    touchMDT for touchRESPIRATORYListen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK.This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.For further information visit our website:  www.touchRESPIRATORY.com

    16 min

  7. 13 NOV

    touchMDT for touchRESPIRATORY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?

    touchMDT for touchRESPIRATORY What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? Listen to key experts Prof. Suresh Senan, Dr Lizza Hendriks and Dr Jacob Sands discuss the impact of ICIs on the real-world management of patients with LS-SCLC, including guidance on monitoring for and management of possible immune-related side effects. The multidisciplinary team Radiation oncologist – Prof. Suresh SenanAmsterdam University Medical Center, Amsterdam, The Netherlands Pulmonologist – Dr Lizza Hendriks, Maastricht University Medical Center, Maastricht, The Netherlands Medical oncologist – Dr Jacob SandsDana-Farber Cancer Institute, Boston, MA, USA This touchPODCAST is for HCPs outside the UK. This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchrespiratoryime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/

    15 min

  8. 13 NOV

    touchMDT for touchRESPIRATORY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?

    touchMDT for touchRESPIRATORY What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? Listen to experts Dr Jacob Sands and Prof. Suresh Senan discuss the latest data for ICIs in LS-SCLC, including data released at key congresses in 2024, and share their clinical insights. The multidisciplinary team Medical oncologist – Dr Jacob SandsDana-Farber Cancer Institute, Boston, MA, USA Radiation oncologist – Prof. Suresh SenanAmsterdam University Medical Center, Amsterdam, The Netherlands This touchPODCAST is for HCPs outside the UK. This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchrespiratoryime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/

    14 min
See All (100)

About

Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.

Information

  • Creator
    touchpodcast
  • Years Active
    2020 - 2024
  • Episodes
    100
  • Rating
    Clean
  • Copyright
    © Copyright 2020 All rights reserved.
  • Show Website
    touchPODCAST

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada